Top Abstract Purchase Related
Home
>
Node
>
Subnode

Simultaneous quantitation of nucleoside HIV-1 reverse transcriptase inhibitors by short-end injection capillary electrochromatography on a beta-cyclodextrin-bonded silica stationary phase

Mesplet, N.; Morin, P.; François, C.; Agrofoglio, L.A.

Journal of Chromatography A 927(1-2): 161-168

2001

ISSN/ISBN: 0021-9673
PMID: 11572385
Document Number: 536179
As part of our on-going study of the analysis and quantitation of anti-HIV nucleosides, a capillary electrochromatography (CEC) method has been developed for the simultaneous quantitation of nucleoside HIV reverse transcriptase inhibitors (NRTIs), i.e. zidovudine (AZT), lamivudine (3TC), didanosine (ddA) and its administrated form (ddI), stavudine (d4T) and hivid (ddC). CEC on chiral stationary phase has mainly been dedicated to the separation of enantiomers. However, this paper explores an original application of a beta-cyclodextrin-bonded silica packed column, taking advantage of the internal hydrophobicity of the polysaccharide to separate the NRTIs. The influence of several parameters (pH buffer, ionic strength, acetonitrile content, temperature and voltage) has been investigated using the short-end injection technique to achieve baseline separation in a short-time analysis before quantitation.

Document emailed within 1 workday
Secure & encrypted payments

Chen, Z.; Zeng, S.; Yao, T. 2007: Separation of beta-receptor blockers and analogs by capillary liquid chromatography (CLC) and pressurized capillary electrochromatography (pCEC) using a vancomycin chiral stationary phase column Die Pharmazie 62(8): 585-592
Engchanil, C.; Kosalaraksa, P.; Lulitanond, V.; Lumbiganon, P.; Chantratita, W. 2006: Multi-drug resistant HIV-1 reverse transcriptase genotype in children treated with dual nucleoside reverse transcriptase inhibitors (NRTIs) Journal of the Medical Association of Thailand 89(10): 1713-1720
Xu, L.; Li, L.; Yang, H. 2007: Preparation, characterization and chromatographic performance of curcumin bonded silica stationary phase Se Pu 25(3): 374-379
Brzezińska, E.; Glinka, R. 2002: Search for new non-nucleoside inhibitors of HIV-1 reverse transcriptase (HIV-1 RT) Acta Poloniae Pharmaceutica 59(5): 379-386
2000: Non-nucleoside reverse transcriptase inhibitors. First line therapy MMW Fortschritte der Medizin 142(3 Suppl): 34-35
Qin, S.; Zhou, C.; Zhu, Y.; Ren, Z.; Zhang, L.; Fu, H.; Zhang, W. 2011: Characteristics of electroosmotic flow in open-tubular capillary electrochromatography with magnetic nanoparticle coating as mixed-mode stationary phase Se Pu 29(9): 942-946
Tarby, C.M. 2004: Recent advances in the development of next generation non-nucleoside reverse transcriptase inhibitors Current Topics in Medicinal Chemistry 4(10): 1045-1057
Wainberg, M.A.; Sawyer, J.P.C.; Montaner, J.S.G.; Murphy, R.L.; Kuritzkes, D.R.; Raffi, F. 2005: Challenges for the clinical development of new nucleoside reverse transcriptase inhibitors for HIV infection Antiviral Therapy 10(1): 13-28
Stankov, M.V.; Lücke, T.; Das, A.M.; Schmidt, R.E.; Behrens, G.M.N. 2007: Relationship of mitochondrial DNA depletion and respiratory chain activity in preadipocytes treated with nucleoside reverse transcriptase inhibitors Antiviral Therapy 12(2): 205-216
Flandre, P.; Descamps, D.; Joly, V.; Meiffrédy, V.; Tamalet, C.; Izopet, J.; Aboulker, J-Pierre.; Brun-Vézinet, Fçoise. 2003: Predictive factors and selection of thymidine analogue mutations by nucleoside reverse transcriptase inhibitors according to initial regimen received Antiviral Therapy 8(1): 65-72
Vemula, S.; Kerr, S.; Pancharoen, C.; Siripong, A.; Kosalaraksa, P.; Engchanil, C.; Chuamchaitrakool, A.; Intasan, J.; Lumbiganond, P.; Phanuphak, P.; Ananworanich, J. 2007: Incidence and risk factors for non-nucleoside reverse transcriptase inhibitors (NNRTI)-related rash in Thai children with HIV infection Journal of the Medical Association of Thailand 90(11): 2437-2441
Sachdeva, R.K.; Wanchu, A.; Bagga, R.; Malla, N.; Sharma, M. 2010: Effect of non-nucleoside reverse transcriptase inhibitors on cytokine, chemokine, and immunoglobulin profiles in serum and genital secretions of HIV-infected women Journal of Interferon and Cytokine Research: the Official Journal of the International Society for Interferon and Cytokine Research 30(5): 299-310
Mankhatitham, W.; Luaengniyomkul, A.; Manosuthi, W. 2012: Lipid profile changes in Thai HIV and tuberculosis co-infected patients receiving non-nucleoside reverse transcriptase inhibitors-based antiretroviral therapy Journal of the Medical Association of Thailand 95(2): 163-169
Arenas-Pinto, A.; Bhaskaran, K.; Dunn, D.; Weller, I.V.D. 2008: The risk of developing peripheral neuropathy induced by nucleoside reverse transcriptase inhibitors decreases over time: evidence from the Delta trial Antiviral Therapy 13(2): 289-295
Ramachandran, G.; Kumar, A.K.Hemanth.; Ponnuraja, C.; Ramesh, K.; Rajesh, L.; Chandrasekharan, C.; Swaminathan, S. 2013: Lack of association between plasma levels of non-nucleoside reverse transcriptase inhibitors & virological outcomes during rifampicin co-administration in HIV-infected TB patients Indian Journal of Medical Research 138(6): 955-961
Song, L.; Ding, S.; Ge, Z.; Zhu, X.; Qiu, C.; Wang, Y.; Lai, E.; Yang, W.; Sun, Y.; Chow, S.A.; Yu, L. 2018: Nucleoside/nucleotide reverse transcriptase inhibitors attenuate angiogenesis and lymphangiogenesis by impairing receptor tyrosine kinases signalling in endothelial cells British Journal of Pharmacology 175(8): 1241-1259
Berezovskaia, I.V.; Chudinov, M.V. 2005: Ester derivatives of nucleoside inhibitors of reverse transcriptase: I. Molecular transport systems for 3'-azido-3'-deoxythymidine and 2',3'-didehydro-3'-deoxythymidine Bioorganicheskaia Khimiia 31(4): 339-356
Reinis, M.; Vandasová, J.; Stanková, M.; Linka, M.; Brůcková, M. 2001: Human immunodeficiency virus 1 strains resistant to nucleoside inhibitors of reverse transcriptase in isolates from the Czech Republic as monitored by line probe assay and nucleotide sequencing Acta Virologica 45(5-6): 279-286
Berezovskaia, I.V.; Chudinov, M.V. 2005: Ester derivatives of nucleoside inhibitors of reverse transcriptase: II. Molecular systems for combined therapy with 3'-azido-3'-deoxythymidine and 2',3'-didehydro-3'-deoxythymidine Bioorganicheskaia Khimiia 31(5): 451-465
Lalezari, J.P.; DeJesus, E.; Northfelt, D.W.; Richmond, G.; Wolfe, P.; Haubrich, R.; Henry, D.; Powderly, W.; Becker, S.; Thompson, M.; Valentine, F.; Wright, D.; Carlson, M.; Riddler, S.; Haas, F.F.; DeMasi, R.; Sista, P.R.; Salgo, M.; Delehanty, J. 2003: A controlled Phase Ii trial assessing three doses of enfuvirtide (T-20) in combination with abacavir, amprenavir, ritonavir and efavirenz in non-nucleoside reverse transcriptase inhibitor-naive HIV-infected adults Antiviral Therapy 8(4): 279-287